Flowvium
एक्सप्लोरर पर वापस जाएं

Regeneron Pharmaceuticals

REGNintermediary

Regeneron is a leading biotechnology company built on its proprietary VelociSuite antibody-discovery platform. Dupixent has become one of the best-selling drugs globally, and the company's deep pipeline of bispecific antibodies and next-gen immunotherapies positions it for continued growth beyond its current blockbusters.

शेयर करें:
⇄ Compare

उत्पाद और राजस्व

उत्पाद राजस्व हिस्सा

राजस्व विवरण ($16.2B)

स्थैतिक डेटा (लाइव वित्तीय लोड हो रहे हैं…)

Dupixent (net collaboration) (52%)
Eylea (U.S.) (25%)
Oncology (Libtayo) (10%)
Other Products & Collaboration (13%)

सेगमेंट संरचना और प्रमुख ग्राहक

उत्पाद विवरण

Dupixent (dupilumab)52%

IL-4/IL-13 antibody for atopic dermatitis, asthma, COPD, and allergic conditions

Eylea / Eylea HD25%

Anti-VEGF injection for wet AMD and diabetic eye disease

Libtayo (cemiplimab)8%

PD-1 checkpoint inhibitor for skin and lung cancers

Kevzara (sarilumab)3%

IL-6 receptor antibody for rheumatoid arthritis

Antibody Pipeline (bispecifics, LAG-3)12%

Next-generation bispecific antibodies and combination cancer immunotherapies

आपूर्ति श्रृंखला संबंध

प्रतिस्पर्धी

Eli Lilly and Company

Immunology, antibody therapies

प्रभाव: Competing in biologics

Moderna, Inc.

Cancer immunotherapy

प्रभाव: Competing in oncology

Novo Nordisk

Metabolic disease overlap

प्रभाव: Limited overlap

साझेदार

Pfizer Inc.

Potential collaboration

प्रभाव: Collaborative pipeline

व्यापक एवं बाजार संदर्भ

제약 / 바이오क्षेत्र समाचार

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

आगामी उत्प्रेरक

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

आपूर्ति श्रृंखला समस्याएं

★ 기회Dupixent 적응증 10개 돌파 — 최대 블록버스터 예약
2026-04

COPD 추가 FDA 승인으로 Dupixent 총 적응증 10개. 2030년 $20B 매출 전망으로 글로벌 최대 단일 의약품 등극 예상.

↑ 생산 확대아일랜드 리머릭 바이오 제조시설 확충
2026-03

Dupixent 수요 급증 대비 아일랜드 공장 bioreactor 20만리터 추가. 2027년 완공, 생산 병목 해소.

संस्थागत संकेत

संस्थाकार्रवाईमूल्यतिमाहीफाइलिंग तिथि
BlackRockaccumulating$253M2024.062024-08-13↑
BlackRockreducing$97M2024.062024-08-13↓
BlackRockreducing$122M2024.062024-08-13↓
BlackRockreducing$7M2024.062024-08-13↓
BlackRockreducing$16M2024.062024-08-13↓
BlackRockaccumulating$173M2024.062024-08-13↑
BlackRockaccumulating$186M2024.062024-08-13↑
BlackRockaccumulating$3.4B2024.062024-08-13↑
BlackRockaccumulating$2.4B2024.062024-08-13↑
BlackRockaccumulating$155M2024.062024-08-13↑
BlackRockaccumulating$260M2024.062024-08-13↑
BlackRockreducing$108M2024.062024-08-13↓
BlackRockaccumulating$263M2024.062024-08-13↑
BlackRockreducing$2M2024.062024-08-13↓
BlackRockaccumulating$985M2024.062024-08-13↑
BlackRockreducing$30M2024.062024-08-13↓
BlackRockreducing$35M2024.062024-08-13↓
BlackRockaccumulating$186M2024.062024-08-13↑
BlackRockreducing$24M2024.062024-08-13↓
BlackRockreducing$5M2024.062024-08-13↓
BlackRockaccumulating$145M2024.062024-08-13↑
Vanguard Groupaccumulating$42M2025.122026-01-29↑
Vanguard Groupaccumulating$171M2025.122026-01-29↑
Vanguard Groupaccumulating$433M2025.122026-01-29↑
Vanguard Groupaccumulating$130M2025.122026-01-29↑
Vanguard Groupaccumulating$6.2B2025.122026-01-29↑
Vanguard Groupaccumulating$28K2025.122026-01-29↑
State Streetaccumulating$3.6B2025.122026-02-13↑
Wellington Managementaccumulating$501M2025.122026-02-17↑
Wellington Managementreducing$796K2025.122026-02-17↓
Wellington Managementreducing$1M2025.122026-02-17↓
Wellington Managementreducing$575K2025.122026-02-17↓
Wellington Managementreducing$514K2025.122026-02-17↓
Wellington Managementreducing$175K2025.122026-02-17↓
Wellington Managementaccumulating$6M2025.122026-02-17↑
Wellington Managementaccumulating$2M2025.122026-02-17↑
FMR (Fidelity)accumulating$1.4B2025.122026-02-17↑
FMR (Fidelity)reducing$76K2025.122026-02-17↓
FMR (Fidelity)accumulating$161M2025.122026-02-17↑
FMR (Fidelity)accumulating$211M2025.122026-02-17↑
FMR (Fidelity)reducing$8M2025.122026-02-17↓
FMR (Fidelity)reducing$36M2025.122026-02-17↓

संस्थागत स्वामित्व

13F आधार · Q4 2025
संस्थापरिवर्तनस्वामित्व %पिछली तिमाहीशेयरमूल्यSEC
Baillie Giffordबनाए रखा1.70%—1.6M शेयर$1,800M13F
Wellingtonबढ़ाई गई1.10%—1.0M शेयर$1,100M13F
Capital Groupबढ़ाई गई0.85%—0.8M शेयर$890M13F
T. Rowe Priceबढ़ाई गई0.62%—0.6M शेयर$650M13F
कुल ट्रैक स्वामित्व: 4.27%कुल मूल्य: $4,440MSEC EDGAR 13F-HR के आधार पर · 45-दिन की देरी

ताज़ा खबर

समाचार लोड हो रहा है...

AI विश्लेषण

Regeneron Pharmaceuticals का AI आपूर्ति श्रृंखला विश्लेषण प्राप्त करने के लिए "AI विश्लेषण प्राप्त करें" पर क्लिक करें।

कंपनी जानकारी

मुख्यालय

Tarrytown, New York, USA

स्थापना

1988

कर्मचारी

14,000+

वेबसाइट

regeneron.com

न्यूज़ गैप स्कोर

गैप स्कोर80
कम गैपअधिक गैप

संस्थागत गतिविधि

82

मीडिया स्कोर

20

कैस्केड स्थिति

कैस्केड में भूमिका

late mover

सामान्य देरी

2-5 trading days

Regeneron's antibody platform may produce GLP-1 alternatives; the company reacts to obesity-market sizing and competitive dynamics.

पूरा कैस्केड देखें

क्षेत्र अवलोकन — 제약 / 바이오

क्षेत्र समाचार

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

मुख्य विषय

  • •Mounjaro/Wegovy — 비만·당뇨 넘어 심혈관·신장·NASH 적응증 확대
  • •Moderna mRNA-4157 암백신 — 흑색종 49% 재발 감소 (NEJM)
  • •REGN dupilumab 다적응증 확대 → 10조+ 매출 가시성

आगामी उत्प्रेरक

  • ◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)
  • ◆MRNA 암백신 FDA BLA 제출 예정